CTLA4 and breast carcinoma: CTLA4 and PD-L1, both known as two immunosuppressants commonly used in breast cancer, showed higher expression levels in DJ-1 high expression group (P=0.03 for CTLA4 and P = 1.11 × 10−9 for PD-L1) (Figure 6(c)).